Corcept Therapeutics Inc. Receives Orphan Drug Designation for CORLUX(R) Treatment of Cushing's Syndrome
MENLO PARK, CA--(MARKET WIRE)--Jul 9, 2007 -- Corcept Therapeutics Incorporated (NasdaqCM:CORT - News) today announced that it has received Orphan Drug Designation from the Food and Drug Administration (FDA) for CORLUX for the treatment of Cushing's Syndrome. CORLUX is a cortisol receptor (GR-II) antagonist.